Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Controlled, Masked, Multi-center Study Evaluating the Efficacy, Safety, and Tolerability of Two Doses of AGTC-501 Compared to an Untreated Control Group in Male Participants With X-linked Retinitis Pigmentosa

NCT04850118 is registered in ClinicalTrials.gov with Beacon Therapeutics as lead sponsor.

NCT NCT04850118
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04850118 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Controlled, Masked, Multi-center Study Evaluating the Efficacy, Safety, and Tolerability of Two Doses of AGTC-501 Compared to an Untreated Control Group in Male Participants With X-linked Retinitis Pigmentosa
Lead sponsor
Beacon Therapeutics
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
March 14, 2024
Completion date
October 31, 2031
Enrollment
85 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

x-linked retinitis pigmentosa